HOME >> MEDICINE >> NEWS
Cure Rate Soars For Some AML Patients Receiving High-Dose Drug

COLUMBUS, Ohio -- A drug given at levels substantially higher than the standard dose can cure nearly five times as many patients who have a certain type of acute myeloid leukemia (AML), new research shows.

The study revealed that 78 percent of patients with “core binding factor” AML who received the drug cytarabine at high dose were in complete remission five years after treatment (and therefore potentially cured) compared to only 16 percent who received the standard dose.

“It is truly remarkable to achieve a cure rate of over 75 percent in a subgroup of adult leukemia patients; this rate approaches that for some types of childhood leukemia,” said Clara Bloomfield, director of Ohio State University's Comprehensive Cancer Center and William G. Pace III Professor of Cancer Research.

“Because high-dose cytarabine is quite toxic, especially for older people, we want to use it only with those patients who will benefit. These results tell us which patients we can cure, and which ones should receive other therapy.”

The finding is considered particularly strong because the study had followed patients for more than seven years after treatment; most such studies rely on models to project estimates of five-year remission rates.

The study, which was led by Bloomfield, appeared in the September issue of the journal Cancer Research. It involved 285 newly diagnosed AML patients aged 16 and older who were in remission. During the second phase of their treatment, a phase known as “intensification therapy,” the patients were randomly assigned to receive cytarabine at either standard dose (100 milligrams per square meter
'"/>

Contact: Clara Bloomfield
bloomfield-1@medctr.osu.edu
614-293-7518
Ohio State University
29-Oct-1998


Page: 1 2 3

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Patients with cancer have highly increased risk for blood clots
3. Patients with previous heart attacks may not benefit from pacemaker implant
4. Patients with cancer detected on screening mammography undergo less toxic treatment
5. Patients with moderate or severe hand dermatitis responsive to drug therapy
6. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
7. Patients who are intubated prior to hospital arrival fare worse find Pitt researchers
8. Patients undergoing weight loss surgery have high rates of H pylori bacteria
9. Patients with chronic sinus do not necessarily develop antibiotic resistance
10. Plastic surgeons honor Patients of Courage overcoming difficult obstacles, inspiring others
11. Patients with severe depression improve using guidelines developed by UT Southwestern researchers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cure Rate Soars For Some AML Patients Receiving High Dose Drug

(Date:10/31/2014)... 2014 Energy Textiles has recently added ... gear is now available online, and Energy Textile is ... Celliant infrared-active athletic gear over compression gear. , ... has been signed for Under Armour to provide team ... eight years. In light of this decision, Energy Textiles ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... Gold Medal Wine Club is making it ... for the wine novice and enthusiasts on their lists with ... , which Early Bird shoppers receive discounts as high as ... , Gift Givers must place their orders before November ... Gold Medal Wine Club adds more value to its Wine ...
(Date:10/31/2014)... a drug combination that can trigger the self-destruct process ... new treatments, according to research that will be presented ... in Liverpool next week*. , When healthy cells are ... culminating in self destruction. But cancer cells swerve away ... that cells grow out of control – causing tumours ...
(Date:10/31/2014)... 2014 Triple Board Certified surgeon ... services to transform the appearance of military veteran Joseph ... of Facial Plastic and Reconstruction Surgery (AAFPRS) Faces of ... the facial hair Jones lost during an IED blast ... hair restoration procedure, valued around $16,000, took Dr. Epstein ...
Breaking Medicine News(10 mins):Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
(Date:10/31/2014)... , Oct. 31, 2014  Digirad Corporation (Nasdaq: DRAD) today ... Inc. (Nasdaq: PDII ), a healthcare commercialization ... proposal to acquire the company.  Digirad ... regarding a transaction and to operate in the ordinary ... or take on additional debt, on acquisitions or other ...
(Date:10/31/2014)... -- Grammy Award-winner Bruce Hornsby will give an ... actors, and musicians during the 10 th Annual ... Mandarin Oriental Hotel in New York City ... individuals who embody the values of the Orthopaedic Foundation. ... honor, the Spirit of an Active Lifestyle Award, to ...
(Date:10/31/2014)... Oct. 31, 2014  Australian biopharmaceutical company Specialised Therapeutics ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be ... with metastatic pancreatic cancer from 1 November. ... is the 5 th most common cause of ... cancer deaths, with the lowest 5-year survival of all ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 510th Anniversary Orthopaedic Foundation Gala Set For Success 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8
Cached News: